SCHEMBL19632445

SCHEMBL19632445

CC(C)CC1Cc2cccnc2C1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD3 P35462 2/20 0.41
DRD2 P14416 1/20 0.41
LNPEP Q9UIQ6 1/20 0.37
ADORA2A P29274 1/20 0.36
DPP8 Q6V1X1 1/20 0.35
DPP9 Q86TI2 1/20 0.35
CYP19A1 P11511 1/20 0.34
OPRM1 P35372 1/20 0.34
OPRK1 P41145 1/20 0.34
CYP2D6 P10635 3/20 0.33
BUB1 O43683 1/20 0.33
PRCP P42785 1/20 0.33
NAMPT P43490 2/20 0.32
GRIN1 Q05586 2/20 0.32
GRIN2B Q13224 2/20 0.32
GRM4 Q14833 1/20 0.31
CCNA2 P20248 1/20 0.31
CDK2 P24941 1/20 0.31
CCNA1 P78396 1/20 0.31
ADRA2A P08913 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24993144 0.86 DRD2 (0.51) DRD3DRD2LNPEPDPP8DPP9
SCHEMBL22652290 0.86 DRD2 (0.42) DRD3DRD2DPP8DPP9CYP19A1
SCHEMBL13291929 0.81 DRD3 (0.48) DRD3DRD2ADORA2ADPP8DPP9
SCHEMBL14824572 0.78 OPRM1 (0.45) DRD3DRD2CYP19A1OPRM1OPRK1
SCHEMBL5095565 0.77 DRD2 (0.41) DRD3DRD2ADORA2ADPP8DPP9
SCHEMBL24993142 0.75 CCNA2 (0.38) DRD3DRD2LNPEPDPP8DPP9
SCHEMBL3498480 0.74 DRD3 (0.44) DRD3DRD2ADORA2ACYP2D6GRIN1
SCHEMBL13998639 0.74 DRD3 (0.44) DRD3DRD2ADORA2ACYP2D6GRIN1
SCHEMBL13998641 0.74 DRD3 (0.44) DRD3DRD2ADORA2ACYP2D6GRIN1
SCHEMBL8376129 0.74 DRD2 (0.41) DRD3DRD2DPP8DPP9CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023180189-A1 MPRO TARGETING ANTIVIRAL COMPOUNDS EXSCIENTIA AI LIMITED (GB) 2023-09-28 WO disclosed
US-20170333398-A1 HETEROCYCLIC DERIVATIVE HAVING AMPK-ACTIVATING ACTIVITY SHIONOGI & CO., LTD. (JP) 2017-11-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170333398-A1 HETEROCYCLIC DERIVATIVE HAVING AMPK-ACTIVATING ACTIVITY PRKAR2B, PRKAR2A, PRKAG3 DRD3 1598/4885DRD2 2062/4885LNPEP 4428/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.